Communiqués Mabpharm Limited

Actions

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:04 27/07/2026			Varia. 5j.	Varia. 1 janv.
0,4000 ^HKD	-2,44%		-1,23%	-20,00%

24/06	Mabpharm Limited obtient l'approbation de sa demande de nouveau medicament pour le CMAB807X (Denosumab en injection)	CI
09/06	Mabpharm Limited obtient l'approbation de la NMPA pour la mise sur le marché du CMAB807 (dénosumab en injection)	CI

20/07/21	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/04/21	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/04/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/04/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU
12/04/21	Mabpharm : FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, APRIL 30, 2021	PU
25/03/21	Mabpharm : DELAY IN DESPATCH OF CIRCULAR	PU
01/03/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) CHANGE IN USE OF PROCEEDS	PU
14/08/20	Mabpharm : SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2019	PU